Indication
Low Risk
1 clinical trial
1 product
Clinical trial
A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)Status: Recruiting, Estimated PCD: 2025-05-01
Product
Etavopivat